{"id":"https://openalex.org/W4389220822","doi":"https://doi.org/10.1182/blood-2023-183034","title":"Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis","display_name":"Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis","publication_year":2023,"publication_date":"2023-11-02","ids":{"openalex":"https://openalex.org/W4389220822","doi":"https://doi.org/10.1182/blood-2023-183034"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2023-183034","doi":"https://doi.org/10.1182/blood-2023-183034","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1182/blood-2023-183034","pdf_url":"https://ashpublications.org/blood/article-pdf/142/Supplement 1/2129/2192299/blood-8732-main.pdf","source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://ashpublications.org/blood/article-pdf/142/Supplement 1/2129/2192299/blood-8732-main.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5054146743","display_name":"Christina Poh","orcid":"https://orcid.org/0000-0003-3120-712X","observed_orcids":["https://orcid.org/0000-0003-3120-712X"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christina Poh","raw_affiliation_strings":["1Fred Hutchinson Cancer Center, Seattle, WA","2Division of Hematology and Oncology, University of Washington, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fred Hutchinson Cancer Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]},{"raw_affiliation_string":"2Division of Hematology and Oncology, University of Washington, Seattle, WA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087798161","display_name":"Victor A. Chow","orcid":"https://orcid.org/0000-0002-3290-3904","observed_orcids":["https://orcid.org/0000-0002-3290-3904"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Victor A Chow","raw_affiliation_strings":["1Fred Hutchinson Cancer Center, Seattle, WA","2Division of Hematology and Oncology, University of Washington, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fred Hutchinson Cancer Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]},{"raw_affiliation_string":"2Division of Hematology and Oncology, University of Washington, Seattle, WA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005281918","display_name":"Ryan C. Lynch","orcid":"https://orcid.org/0000-0001-6703-0894","observed_orcids":["https://orcid.org/0000-0001-6703-0894"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan C Lynch","raw_affiliation_strings":["1Fred Hutchinson Cancer Center, Seattle, WA","2Division of Hematology and Oncology, University of Washington, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fred Hutchinson Cancer Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]},{"raw_affiliation_string":"2Division of Hematology and Oncology, University of Washington, Seattle, WA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079426839","display_name":"Chaitra Shankar Ujjani","orcid":"https://orcid.org/0000-0003-1977-1510","observed_orcids":["https://orcid.org/0000-0003-1977-1510","https://orcid.org/0000-0003-2662-4826"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chaitra S Ujjani","raw_affiliation_strings":["1Fred Hutchinson Cancer Center, Seattle, WA","2Division of Hematology and Oncology, University of Washington, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fred Hutchinson Cancer Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]},{"raw_affiliation_string":"2Division of Hematology and Oncology, University of Washington, Seattle, WA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051296565","display_name":"Mazyar S. Shadman","orcid":"https://orcid.org/0000-0002-3365-6562","observed_orcids":["https://orcid.org/0000-0002-3365-6562"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mazyar Shadman","raw_affiliation_strings":["1Fred Hutchinson Cancer Center, Seattle, WA","2Division of Hematology and Oncology, University of Washington, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fred Hutchinson Cancer Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]},{"raw_affiliation_string":"2Division of Hematology and Oncology, University of Washington, Seattle, WA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037938194","display_name":"Brian G. Till","orcid":"https://orcid.org/0000-0002-4718-8288","observed_orcids":["https://orcid.org/0000-0002-4718-8288"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian G Till","raw_affiliation_strings":["1Fred Hutchinson Cancer Center, Seattle, WA","2Division of Hematology and Oncology, University of Washington, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fred Hutchinson Cancer Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]},{"raw_affiliation_string":"2Division of Hematology and Oncology, University of Washington, Seattle, WA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001831770","display_name":"Vikram M. Raghunathan","orcid":"https://orcid.org/0000-0002-6026-4134","observed_orcids":["https://orcid.org/0000-0002-6026-4134","https://orcid.org/0000-0001-5324-2431"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vikram Raghunathan","raw_affiliation_strings":["1Fred Hutchinson Cancer Center, Seattle, WA","2Division of Hematology and Oncology, University of Washington, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fred Hutchinson Cancer Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]},{"raw_affiliation_string":"2Division of Hematology and Oncology, University of Washington, Seattle, WA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064080252","display_name":"Edus Houston Warren","orcid":"https://orcid.org/0000-0002-9570-2755","observed_orcids":["https://orcid.org/0000-0002-9570-2755"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edus H Warren","raw_affiliation_strings":["1Fred Hutchinson Cancer Center, Seattle, WA","2Division of Hematology and Oncology, University of Washington, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fred Hutchinson Cancer Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]},{"raw_affiliation_string":"2Division of Hematology and Oncology, University of Washington, Seattle, WA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010158325","display_name":"Jordan Gauthier","orcid":"https://orcid.org/0000-0002-5769-8409","observed_orcids":["https://orcid.org/0000-0002-5769-8409"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jordan Gauthier","raw_affiliation_strings":["1Fred Hutchinson Cancer Center, Seattle, WA","2Division of Hematology and Oncology, University of Washington, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fred Hutchinson Cancer Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]},{"raw_affiliation_string":"2Division of Hematology and Oncology, University of Washington, Seattle, WA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088459737","display_name":"Stephen Douglas Smith","orcid":"https://orcid.org/0000-0001-5354-7593","observed_orcids":["https://orcid.org/0000-0001-5354-7593"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen D Smith","raw_affiliation_strings":["1Fred Hutchinson Cancer Center, Seattle, WA","2Division of Hematology and Oncology, University of Washington, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fred Hutchinson Cancer Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]},{"raw_affiliation_string":"2Division of Hematology and Oncology, University of Washington, Seattle, WA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022390160","display_name":"Taranjit S. Gujral","orcid":"https://orcid.org/0000-0002-4453-3031","observed_orcids":["https://orcid.org/0000-0002-4453-3031","https://orcid.org/0000-0001-9030-3053"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Taran Gujral","raw_affiliation_strings":["1Fred Hutchinson Cancer Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fred Hutchinson Cancer Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086380045","display_name":"Chihiro Morishima","orcid":"https://orcid.org/0000-0001-5330-9464","observed_orcids":["https://orcid.org/0000-0001-5330-9464"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chihiro Morishima","raw_affiliation_strings":["1Fred Hutchinson Cancer Center, Seattle, WA","3Division of Laboratory Medicine, University of Washington, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fred Hutchinson Cancer Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]},{"raw_affiliation_string":"3Division of Laboratory Medicine, University of Washington, Seattle, WA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027819567","display_name":"Qian Vicky Wu","orcid":"https://orcid.org/0000-0002-2292-4816","observed_orcids":["https://orcid.org/0000-0002-2292-4816"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Qian Wu","raw_affiliation_strings":["1Fred Hutchinson Cancer Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fred Hutchinson Cancer Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057524392","display_name":"Jenna M. Voutsinas","orcid":"https://orcid.org/0000-0002-7474-4892","observed_orcids":["https://orcid.org/0000-0002-7474-4892"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jenna M Voutsinas","raw_affiliation_strings":["1Fred Hutchinson Cancer Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fred Hutchinson Cancer Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068932941","display_name":"Amy Sperling","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amy Sperling","raw_affiliation_strings":["2Division of Hematology and Oncology, University of Washington, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Division of Hematology and Oncology, University of Washington, Seattle, WA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Joshua Dizon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joshua Dizon","raw_affiliation_strings":["2Division of Hematology and Oncology, University of Washington, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Division of Hematology and Oncology, University of Washington, Seattle, WA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016684714","display_name":"David G. Maloney","orcid":"https://orcid.org/0000-0002-8477-6919","observed_orcids":["https://orcid.org/0000-0002-8477-6919"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David G Maloney","raw_affiliation_strings":["1Fred Hutchinson Cancer Center, Seattle, WA","2Division of Hematology and Oncology, University of Washington, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fred Hutchinson Cancer Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]},{"raw_affiliation_string":"2Division of Hematology and Oncology, University of Washington, Seattle, WA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5004025497","display_name":"Ajay K. Gopal","orcid":"https://orcid.org/0000-0003-3023-6834","observed_orcids":["https://orcid.org/0000-0003-3023-6834"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ajay K Gopal","raw_affiliation_strings":["1Fred Hutchinson Cancer Center, Seattle, WA","2Division of Hematology and Oncology, University of Washington, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fred Hutchinson Cancer Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]},{"raw_affiliation_string":"2Division of Hematology and Oncology, University of Washington, Seattle, WA","institution_ids":["https://openalex.org/I201448701"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5000,"currency":"USD","value_usd":5000},"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":5,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"142","issue":"Supplement 1","first_page":"2129","last_page":"2129"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.989300012588501,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.989300012588501,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.00430000014603138,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0034000000450760126,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acalabrutinib","display_name":"acalabrutinib","score":0.996999979019165},{"id":"https://openalex.org/keywords/axicabtagene-ciloleucel","display_name":"axicabtagene ciloleucel","score":0.9330000281333923},{"id":"https://openalex.org/keywords/cd19-targeted-car-t","display_name":"CD19-targeted CAR-T","score":0.8220000267028809},{"id":"https://openalex.org/keywords/relapsed-refractory-b-cell-lymphoma","display_name":"relapsed/refractory B-cell lymphoma","score":0.9879999756813049},{"id":"https://openalex.org/keywords/large-b-cell-lymphoma","display_name":"large B-cell lymphoma","score":0.9160000085830688},{"id":"https://openalex.org/keywords/follicular-lymphoma","display_name":"follicular lymphoma","score":1.0},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.75},{"id":"https://openalex.org/keywords/bridging-therapy","display_name":"bridging therapy","score":0.7940000295639038},{"id":"https://openalex.org/keywords/cytokine-release-syndrome","display_name":"cytokine release syndrome","score":0.9020000100135803},{"id":"https://openalex.org/keywords/immune-effector-cell-associated-neurotoxicity-syndrome","display_name":"immune effector cell-associated neurotoxicity syndrome","score":0.7900000214576721},{"id":"https://openalex.org/keywords/lymphodepletion","display_name":"lymphocyte depletion","score":0.675000011920929},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.45399999618530273},{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.414000004529953},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.6129999756813049}],"concepts":[{"id":"https://openalex.org/C2780850621","wikidata":"https://www.wikidata.org/wiki/Q3961647","display_name":"Cytokine release syndrome","level":5,"score":0.8241806030273438},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6681010127067566},{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.6567844748497009},{"id":"https://openalex.org/C2777058707","wikidata":"https://www.wikidata.org/wiki/Q123251","display_name":"Follicular lymphoma","level":3,"score":0.5553085207939148},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.43088269233703613},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.42836862802505493},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.42584237456321716},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.42541009187698364},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.37397003173828125},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3657471239566803},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.32701483368873596},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.31572631001472473},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.282335489988327},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.226898193359375}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2023-183034","doi":"https://doi.org/10.1182/blood-2023-183034","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1182/blood-2023-183034","pdf_url":"https://ashpublications.org/blood/article-pdf/142/Supplement 1/2129/2192299/blood-8732-main.pdf","source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1182/blood-2023-183034","doi":"https://doi.org/10.1182/blood-2023-183034","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1182/blood-2023-183034","pdf_url":"https://ashpublications.org/blood/article-pdf/142/Supplement 1/2129/2192299/blood-8732-main.pdf","source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320308573","display_name":"Gilead Sciences","ror":"https://ror.org/056546b03"},{"id":"https://openalex.org/F4320308793","display_name":"Fred Hutchinson Cancer Research Center","ror":"https://ror.org/007ps6h72"},{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"},{"id":"https://openalex.org/F4320311600","display_name":"Regeneron Pharmaceuticals","ror":"https://ror.org/02f51rf24"},{"id":"https://openalex.org/F4320313971","display_name":"TG Therapeutics","ror":"https://ror.org/00pwykz63"},{"id":"https://openalex.org/F4320316491","display_name":"MEI Pharma","ror":"https://ror.org/02bgfrc80"},{"id":"https://openalex.org/F4320316519","display_name":"Angiocrine Bioscience","ror":"https://ror.org/02hpd7j03"},{"id":"https://openalex.org/F4320317235","display_name":"BeiGene","ror":"https://ror.org/012v2c923"},{"id":"https://openalex.org/F4320317544","display_name":"Incyte","ror":"https://ror.org/00cvzzg84"},{"id":"https://openalex.org/F4320319515","display_name":"Seagen","ror":null},{"id":"https://openalex.org/F4320328062","display_name":"MorphoSys","ror":"https://ror.org/00ew7rg06"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"},{"id":"https://openalex.org/F4320333647","display_name":"Kite Pharma","ror":"https://ror.org/05waa9105"},{"id":"https://openalex.org/F4320333648","display_name":"Pharmacyclics","ror":"https://ror.org/03hm8w204"},{"id":"https://openalex.org/F4320333670","display_name":"Juno Therapeutics","ror":"https://ror.org/02dq5dx40"},{"id":"https://openalex.org/F4320334489","display_name":"Legend Biotech","ror":"https://ror.org/04zawcj85"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4389220822.pdf","grobid_xml":"https://content.openalex.org/works/W4389220822.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4405049132","https://openalex.org/W3037190766","https://openalex.org/W2985210500","https://openalex.org/W2910261501","https://openalex.org/W7108444565","https://openalex.org/W2966873510","https://openalex.org/W3031546681","https://openalex.org/W3024551293","https://openalex.org/W4391630741","https://openalex.org/W4387207896"],"abstract_inverted_index":{"Introduction":[0],"Limitations":[1],"of":[2,25,72,120,239,248,260,289,356,364,388,401,519,557,564,585,605,624],"effective":[3,108],"CD19-targeted":[4,94],"chimeric":[5],"antigen":[6],"receptor":[7],"T-cell":[8],"therapy":[9],"(CAR-T)":[10],"in":[11,74,122,128,313,632],"relapsed/refractory":[12],"(R/R)":[13],"B-cell":[14,130,156],"lymphoma":[15,160],"include":[16],"inability":[17],"to":[18,22,189,199,210,307,414,416,486,531],"control":[19],"disease":[20,221,379,541],"prior":[21,188,365,413],"CAR-T,":[23,95],"lack":[24],"sustained":[26],"remissions":[27],"following":[28,276],"CAR-T":[29,60,308],"and":[30,43,53,57,63,70,100,102,117,158,185,271,283,302,309,334,337,360,380,422,435,443,457,495,506,574,612,618,640,647,663],"the":[31,68,113,175,361,520,613],"potential":[32],"for":[33,147,305],"life-threatening":[34],"adverse":[35],"effects":[36],"such":[37],"as":[38,106,258],"cytokine":[39],"release":[40],"syndrome":[41,48],"(CRS)":[42],"immune":[44,284],"effector":[45],"cell-associated":[46],"neurotoxicity":[47],"(ICANS).":[49],"BTK":[50],"inhibitors,":[51],"ibrutinib":[52],"acalabrutinib":[54,121,421,481,606],"are":[55,303,311,572,576,616],"immunomodulatory":[56],"may":[58,103],"enhance":[59,97],"expansion,":[61],"engraftment":[62],"tumor":[64],"clearance":[65],"while":[66,538],"decreasing":[67],"frequency":[69],"severity":[71],"CRS":[73,242,442,471,659],"chronic":[75],"lymphocytic":[76],"leukemia":[77],"(Qin,":[78],"et":[79],"al.":[80],"J":[81],"Immunother":[82],"2020).":[83],"Based":[84],"on":[85,237,607],"this,":[86],"we":[87],"hypothesized":[88],"that":[89],"acalabrutinib,":[90],"when":[91,635],"combined":[92],"with":[93,124,152,162,322,326,330,418,455,523,638],"could":[96],"its":[98],"efficacy":[99,116],"safety":[101,235,491],"also":[104,252],"serve":[105],"an":[107,489],"bridging":[109,254],"strategy.":[110],"We":[111,133,251],"report":[112],"initial":[114,389],"safety,":[115],"correlative":[118],"analysis":[119],"combination":[123],"axicabtagene":[125],"ciloleucel":[126],"(axi-cel)":[127],"R/R":[129,153],"lymphoma.":[131],"Methods":[132],"conducted":[134],"a":[135,354,561,583],"phase":[136],"I/II,":[137],"open-label":[138],"trial":[139,634],"(NCT04257578)":[140],"involving":[141],"adult":[142],"patients":[143,151,294,316,393,403,438,448,462,467,479,522,571,631],"meeting":[144,488],"FDA-approved":[145],"criteria":[146],"axi-cel;":[148],"this":[149,633],"included":[150],"CD19+":[154],"large":[155],"(LBCL)":[157],"follicular":[159],"(FL)":[161],"measurable":[163],"disease.":[164],"Acalabrutinib":[165,627],"was":[166,226,234,345,353,367,504,660,666],"continuously":[167],"administered":[168,227],"at":[169,482,498,527,533,543,582,622],"100":[170],"mg":[171],"twice":[172],"daily":[173],"over":[174],"3":[176,183,310,325,338,368,451,521],"study":[177],"phases:":[178],"1)":[179],"Bridging:":[180],"Starting":[181],"between":[182],"weeks":[184],"24":[186],"hours":[187],"leukapheresis":[190,415],"until":[191,217],"lymphodepletion":[192],"(LD),":[193],"2)":[194],"Cell":[195],"therapy:":[196],"From":[197,207],"LD":[198,417],"30":[200,208,246,500,529],"days":[201,209,247],"after":[202,213,655],"axi-cel":[203,214,249,261,277,300,407,502,511,547,579,639],"infusion,":[204,278,432],"3)":[205],"Maintenance:":[206],"1":[211,329,426],"year":[212],"infusion":[215,301,408,503,537],"or":[216,220,243,459,472,476],"unacceptable":[218],"toxicity":[219],"progression":[222,542],"(Figure":[223],"1).":[224,342],"Axi-cel":[225],"per":[228],"institutional":[229],"practice.":[230],"The":[231,493],"primary":[232,377],"endpoint":[233],"based":[236],"rates":[238],"grade":[240,441,450,469,474],"\u22653":[241,470],"ICANS":[244,452,665],"within":[245,385],"infusion.":[250,548,657],"assessed":[253],"success":[255],"rate":[256,269,275,497],"(defined":[257],"receipt":[259],"without":[262],"any":[263,440,473,483],"additional":[264,424],"required":[265],"treatment),":[266],"overall":[267,281],"response":[268,273,285,306],"(ORR)":[270],"complete":[272],"(CR)":[274],"progression-free":[279],"survival,":[280],"survival":[282],"biomarkers.":[286],"Results":[287],"As":[288],"July":[290],"28,":[291],"2023,":[292],"17":[293],"have":[295,298],"enrolled,":[296],"14":[297],"received":[299,427,463],"evaluable":[304],"earlier":[312],"treatment.":[314],"Fourteen":[315,400],"had":[317,339,376,383,394,439,449],"LBCL":[318,372],"(12":[319],"DLBCL":[320],"[4":[321],"double/triple":[323,327],"hit,":[324],"expressor,":[328],"only":[331,652],"MYC":[332],"translocation]":[333],"2":[335,539],"PMBCL)":[336],"FL":[340],"(Table":[341],"Median":[343],"age":[344],"58":[346],"(range":[347,369,566,592],"34-74)":[348],"years,":[349],"largest":[350],"lesion":[351],"diameter":[352],"median":[355,362,562,584],"3.75":[357],"(1.7-7.1)":[358],"cm":[359],"number":[363],"regimens":[366],"1-5).":[370],"Of":[371],"patients,":[373],"6":[374,587],"(43%)":[375],"refractory":[378],"5":[381],"(38%)":[382],"relapsed":[384],"12":[386],"months":[387],"therapy;":[390,425],"4":[391],"(31%)":[392],"previous":[395],"autologous":[396],"stem":[397],"cell":[398,431,656],"transplant.":[399],"15":[402],"(93%)":[404,434],"who":[405],"underwent":[406],"were":[409,514,553,650],"successfully":[410,628],"bridged":[411,629],"from":[412],"single":[419],"agent":[420],"no":[423,515],"added":[428],"radiation.":[429],"After":[430],"13":[433],"8":[436],"(57%)":[437],"ICANS,":[444],"respectively.":[445,508],"Three":[446],"(20%)":[447],"which":[453],"resolved":[454],"dexamethasone":[456],"anakinra":[458],"tocilizumab.":[460],"No":[461,466,478,549],"prophylactic":[464],"dexamethasone.":[465],"experienced":[468],"hemorrhage":[475],"tachyarrhythmia.":[477],"discontinued":[480],"time":[484,556,623],"due":[485],"toxicity,":[487],"interim":[490],"endpoint.":[492],"ORR":[494],"CR":[496,532,644],"day":[499,528,534,544,586],"post":[501,510,536,546],"93%":[505],"71%,":[507],"Through":[509],"maintenance,":[512],"there":[513],"drug":[516],"holds.":[517],"One":[518],"partial":[524],"remission":[525],"(PR)":[526],"converted":[530],"180":[535],"suffered":[540],"90":[545],"treatment":[550],"related":[551],"deaths":[552],"observed":[554,662],"by":[555],"data":[558],"cutoff.":[559],"At":[560],"follow-up":[563],"13.8":[565],"1.7-29.1)":[567],"months,":[568],"10":[569],"(73%)":[570],"alive":[573],"9":[575],"progression-free.":[577],"Post":[578],"cytokines":[580],"peaked":[581],"[median":[588],"IL-6":[589],"196":[590],"pg/ml":[591],"20-11803),":[593],"ferritin":[594,648],"425":[595],"ng/ml":[596],"(156-2051),":[597],"CRP":[598,646],"52.9":[599],"mg/L":[600],"(7.7-239.7),":[601],"Table":[602],"1].":[603],"Impact":[604],"myeloid":[608],"derived":[609],"suppressor":[610],"cells":[611],"immunosecretome":[614],"profile":[615],"underway":[617],"will":[619],"be":[620],"reported":[621],"presentation.":[625],"Conclusions":[626],"most":[630],"given":[636],"concurrently":[637],"safely":[641],"maintained":[642],"high":[643],"rates.":[645],"levels":[649],"typically":[651],"modestly":[653],"elevated":[654],"Severe":[658],"not":[661],"high-grade":[664],"uncommon.":[667]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2024,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-12-02T00:00:00"}